Tonix Pharmaceuticals stock halted ahead of FDA approval news
Oshkosh Corporation’s stock reached a significant milestone, hitting an all-time high of 139.99 USD. With a market capitalization of $8.95 billion and a P/E ratio of 13.86, InvestingPro analysis suggests the stock remains slightly undervalued despite the recent surge. This marks a remarkable achievement for the company, underscoring a strong performance over the past year. The stock’s impressive ascent is further highlighted by a year-to-date return of 47.4% and an overall "GREAT" Financial Health Score from InvestingPro. While technical indicators suggest the stock is in overbought territory, the company’s strategic initiatives and market positioning are resonating well with investors, propelling the stock to new heights. Discover 12 more exclusive insights and a comprehensive Pro Research Report available on InvestingPro.
In other recent news, Oshkosh has reported strong second-quarter earnings, with adjusted earnings per share of $3.41, surpassing consensus estimates by 16%. This performance has led several analyst firms to raise their price targets for the company. UBS increased its price target to $164, citing higher profit and margins across all business segments. DA Davidson also raised its target to $160, noting improvements in the company’s Access segment. Raymond James set a new target of $155, highlighting performance improvements across all operating segments. KeyBanc reiterated its Overweight rating and maintained a $140 price target, expressing confidence in Oshkosh’s progress toward its 2028 targets. Bernstein raised its price target to $132, maintaining a Market Perform rating. These developments reflect the company’s strong financial performance and positive outlook among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.